In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.

Purpose: Peptide receptor radionuclide therapy (PRRT) and somatostatin analogues (SSAs) are commonly combined as primary treatment for neuroendocrine neoplasms (NEN), and SSAs given as maintenance. We sought to evaluate whether sequential therapy with PRRT followed by SSAs has progression or survival benefits in patients with NEN after disease control by PRRT.

Methods: This prospective, randomised, single-centre study had as principal eligibility criteria: unresectable, locally advanced, or metastatic, histologically confirmed well-differentiated NEN; no symptoms/biochemical diagnosis of carcinoid syndrome; no SSAs or ≤ 3 months of SSAs before PRRT; and stable disease or partial or complete response after PRRT.

Intrapancreatic accessory spleen imitating a pancreatic neoplasm.

Accessory spleens are present in 10% of population and are formed during embryonic development. Besides the splenic hilum, the next most frequent localization of accessory spleens is the pancreatic tail. Intrapancreatic accessory spleens are usually diagnosed occasionally and make diagnostic difficulty because they imitate a pancreatic neoplasm.